1,390 results on '"Fleischmann, R."'
Search Results
2. A novel Wnt pathway inhibitor, SM04690, for the treatment of moderate to severe osteoarthritis of the knee: results of a 24-week, randomized, controlled, phase 1 study
3. Dynamical phase diagram of Gaussian BEC wave packets in optical lattices
4. Experimental Observation of a Fundamental Length Scale of Waves in Random Media
5. How branching can change the conductance of ballistic semiconductor devices
6. Avalanches of Bose-Einstein Condensates in Leaking Optical Lattices
7. Fractal Conductance Fluctuations of Classical Origin
8. Sustained Remission and Outcomes with Abatacept plus Methotrexate Following Stepwise Dose De-escalation in Patients with Early Rheumatoid Arthritis
9. Mesoscopic Rectifiers Based on Ballistic Transport: Playing off Classical against Quantum Mechanics
10. Quantum Coherence Beyond the Thermal Length
11. Coherent Branched Flow in a Two-Dimensional Electron Gas
12. Skipping orbits and enhanced resistivity in large-diameter InAs/GaSb antidot lattices
13. Identifying and Quantifying the Role of Inflammation in Pain Reduction for Patients With Psoriatic Arthritis Treated With Tofacitinib: A Mediation Analysis
14. Nonlinear Dynamics of Composite Fermions in Nanostructures
15. Quenched and Negative Hall Effect in Periodic Media: Application to Antidot Superlattices
16. Impact of initial therapy with upadacitinib or adalimumab on achievement of 48-week treatment goals in patients with rheumatoid arthritis: post hoc analysis of SELECT-COMPARE
17. POS0640 OLOKIZUMAB IMPROVED PATIENT REPORTED OUTCOMES IN MTX AND TNF INCOMPLETE RESPONDER RHEUMATOID ARTHRITIS PATIENTS: RESULTS FROM THE LONG TERM EXTENTION TRIAL
18. POS0849 LONG-TERM SAFETY AND EFFICACY OF UPADACITINIB OR ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: 5-YEAR DATA FROM THE SELECT-COMPARE STUDY
19. OP0295 A 12-WEEK, RANDOMIZED, DOUBLE-BLINDED, PLACEBO-CONTROLLED, PHASE 2B STUDY OF SAFETY, TOLERABILITY AND EFFICACY OF AR882 IN GOUT PATIENTS
20. Immunotherapy: MODULATION OF CD6 SPLICE VARIANTS CONTROLS CAR T CELL ACTIVATION
21. The trajectory of clinical responses in patients with early rheumatoid arthritis who achieve sustained remission in response to abatacept
22. Impact clinique de l’arrêt de la corticothérapie chez des patients atteints de polyarthrite rhumatoïde traités par upadacitinib ou adalimumab
23. Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
24. Small Molecule Immunosuppressants in Inflammatory Disease
25. Rehabilitation von Laufverletzungen
26. Ixekizumab, an interleukin-17A specific monoclonal antibody, for the treatment of biologic-naive patients with active psoriatic arthritis: results from the 24-week randomised, double-blind, placebo-controlled and active (adalimumab)-controlled period of the phase III trial SPIRIT-P1
27. POS0683 EFFICACY AND SAFETY OF UPADACITINIB IN TNFi-IR PATIENTS WITH RHEUMATOID ARTHRITIS FROM THREE PHASE 3 CLINICAL TRIALS
28. POS1040 SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 INHIBITOR: AS ASSESSED BY LABORATORY PARAMETERS – RESULTS FROM A PHASE 2 TRIAL IN PSORIATIC ARTHRITIS AND 2 PHASE 3 TRIALS IN PSORIASIS
29. POS0645 LONG-TERM SAFETY AND EFFICACY OF OLOKIZUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS – RESULT OF AN OPEN-LABEL EXTENSION STUDY, CREDO4
30. POS0239 RISK OF VENOUS THROMBOEMBOLIC EVENTS IN PATIENTS WITH RHEUMATOID ARTHRITIS AGED ≥50 YEARS WITH ≥1 CARDIOVASCULAR RISK FACTOR: RESULTS FROM A PHASE 3b/4 RANDOMISED STUDY OF TOFACITINIB VS TUMOUR NECROSIS FACTOR INHIBITORS
31. AB0333 SUSTAINABILITY OF RESPONSE TO UPADACITINIB AMONG PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS REFRACTORY TO BIOLOGICAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
32. POS0643 SUSTAINABILITY OF RESPONSE BETWEEN UPADACITINIB AND ADALIMUMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: RESULTS THROUGH 3 YEARS FROM THE SELECT-COMPARE TRIAL
33. POS0540 CLINICAL OUTCOMES ASSOCIATED WITH GLUCOCORTICOID DISCONTINUATION AMONG PATIENTS WITH RHEUMATOID ARTHRITIS RECEIVING UPADACITINIB OR ADALIMUMAB
34. POS0579 ABSENCE OF ASSOCIATION BETWEEN ABATACEPT EXPOSURE LEVELS AND INITIAL INFECTION IN PATIENTS WITH RA: A POST HOC ANALYSIS OF THE RANDOMIZED, PLACEBO-CONTROLLED AVERT-2 STUDY
35. AB0352 IMPACT OF SEROLOGIC STATUS ON CLINICAL RESPONSES TO UPADACITINIB OR ABATACEPT IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR INADEQUATE RESPONSE TO BIOLOGIC DMARDs: SUB-GROUP ANALYSIS FROM THE PHASE 3 SELECT-CHOICE STUDY
36. P 84 Altered sensorimotor integration of afferent inhibition in patients with complex regional pain syndrome
37. P 85 Impaired pain processing on a brainstem level in patients with complex regional pain syndrome
38. Lithotripsie von Gallengangssteinen mit ESWL und Farbstofflaser
39. Characteristics of lower GI bleeding in critically ill patients: bleeding source and prognosis
40. Impact of upadacitinib or adalimumab as initial therapy on the achievement of 48-week treatment goals in patients with rheumatoid arthritis and inadequate response to methotrexate: Post hoc analysis of a phase 3 study
41. Lack of clinical disease activity response at 4 weeks of baricitinib treatment as a negative predictor of remission at weeks 12 and 24 in patients with rheumatoid arthritis: results from two phase 3 studies (RA-BEAM and RA-BEGIN)
42. Phosphorsaure Zellen und Membranzellen
43. PE.Lu-044 - Traitement du rhumatisme psoriasique par certolizumab pegol : Résultats à 4 ans de l’étude RAPID-PsA
44. O.75 - Comparaison du certolizumab pegol versus adalimumab : résultats d’efficacité et de tolérance à 2 ans d’une étude comparative directe de supériorité, en aveugle pour les investigateurs
45. P.05 - Baricitinib, méthotrexate, ou baricitinib associé au méthotrexate chez les patients ayant une polyarthrite rhumatoïde (PR) récente qui ont reçu peu ou pas de traitements de fond (DMARDs) : Résultats de l’essai de phase 3 RA-BEGIN
46. Indikation der Laserlithotripsie bei Gallengangsteinen
47. Cost-Effective Learning for Classifying Human Values
48. Supplement to: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis.
49. Supplement to: Tofacitinib or adalimumab versus placebo in rheumatoid arthritis.
50. Efficacy and safety of tofacitinib in patients with rheumatoid arthritis that had inadequate response to non-biologic DMARDs or one or more biologic DMARDs including tumor necrosis inhibitors: pooled analysis from Phase 2 and 3 studies.: 185.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.